At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
In Brief
A Phase 3 clinical trial evaluating Standard of care, Apremilast, and 5 other interventions for COVID-19. Completed, enrolled 515 participants across 59 sites in 8 countries.
Detailed Summary
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Study Details
Timeline
Interventions
Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Apremilast administered orally as a tablet.
Matching apremilast placebo administered orally as a tablet.
Lanadelumab administered as an intravenous (IV) infusion.
Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.